The safety of bortezomib for the treatment of multiple myeloma

10.1007/s10555-017-9707-8

10.1158/1078-0432.CCR-16-0625

10.1053/j.seminhematol.2012.04.006

10.1038/nrc1361

10.1200/JCO.2002.01.133

Schwartz R, 2004, Oncology (Williston Park), 18, 14

10.1016/S1535-6108(04)00120-5

Voorhees PM, 2003, Clin Cancer Res, 9, 6316

Jung L, 2004, Oncology (Williston Park), 18, 4

Ma MH, 2003, Clin Cancer Res, 9, 1136

Hideshima T, 2001, Cancer Res, 61, 3071

10.1182/blood-2002-06-1768

10.1016/S0305-7372(03)00079-3

10.1016/S0360-3016(01)01446-8

Sunwoo JB, 2001, Clin Cancer Res, 7, 1419

Nix D, 2003, Paper presented at the 2003 American Association for Cancer Research–National Cancer Institute–European Organization for Research and Treatment of Cancer Molecular Targets and Cancer Therapeutics Discovery, Biology, and Clinical Applications meeting

Nix D, 2003, Paper presented at the Annual Meeting of the American Association of Pharmaceutical Scientists

Lu C, 2003, Paper presented at 12th North American Meeting of the International Society for the Study of Xenobiotics

Jagannath S, 2003, Paper presented at the Annual Meeting of the American Society of Hematology

10.1056/NEJMoa030288

10.1111/j.1365-2141.2008.07359.x

10.1182/blood-2006-08-036947

10.1056/NEJMoa043445

10.1182/blood-2012-11-464503

10.1200/JCO.2011.39.6820

10.6004/jnccn.2017.0023

Jagannath S, 2006, Haematologica, 91, 929

10.1111/j.1365-2141.2008.07409.x

10.3324/haematol.2014.112037

10.1016/S0140-6736(10)61424-9

10.1182/blood-2014-05-576256

10.1182/blood-2011-11-395749

10.1182/blood-2010-02-268862

10.1056/NEJMoa1402551

10.1016/S0140-6736(16)31594-X

10.1056/NEJMoa1611750

10.1056/NEJMoa0801479

10.1200/JCO.2012.41.6180

10.1200/JCO.2009.26.0638

10.1056/NEJMoa1606038

10.1016/S1470-2045(14)70440-1

10.1158/1535-7163.MCT-11-0433

10.1182/blood-2015-09-665018

10.1182/blood-2017-06-788323

10.1016/j.clml.2016.02.042

10.1158/1078-0432.CCR-16-2526

10.1182/blood-2016-01-694604

10.1016/S1470-2045(15)00464-7

Dimopoulos MA, 2018, J Hematol Oncol, 11, 49, 10.1186/s13045-018-0583-7

10.2147/tcrm.2006.2.3.271

10.1038/leu.2011.346

10.1016/S1470-2045(10)70206-0

10.1016/S1470-2045(10)70068-1

10.1016/S1470-2045(11)70081-X

10.3324/haematol.2012.067793

10.1007/s12253-014-9785-7

10.1016/j.clml.2017.03.045

10.1200/JCO.2002.99.502

10.1007/s00520-010-0911-0

10.1200/JCO.2008.18.5017

10.1182/blood-2005-03-1173

10.1038/s41375-018-0040-1

Ghobrial IM, 2016, Blood, 128, 2110, 10.1182/blood.V128.22.2110.2110

10.1634/theoncologist.11-1-51

10.1159/000340050

10.1111/j.1365-2141.2007.06659.x

10.1016/j.cardfail.2014.11.008

10.1182/bloodadvances.2016003269

Millennium Pharmaceuticals Inc. (2017). VELCADE® (bortezomib) for injection, for subcutaneous or intravenous use.

Onyx Pharmaceuticals Inc. (2017). KYPROLIS® (carfilzomib) for injection, for intravenous use.

10.1111/bjh.14708

10.1038/bcj.2015.112

10.1016/j.clml.2017.05.003